Report preliminary data for HIV studies
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 20 Dec 2021
- Due
- 31 Dec 2022
- Delivered
- 31 Jan 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Preliminary data will be reported in 2022.”
What we found
Evidence strength B What the grades mean
ImmunityBio reported preliminary HIV study data in January 2022, within the stated 2022 deadline.
-
B ImmunityBio Announces Promising Clinical Study Results For 'Kick and Kill' HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy
“CULVER CITY, Calif., January 31, 2022 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer (NK) cells in people living with HIV” ✓ confirmed on the page
-
B ImmunityBio Announces Completion of $470 Million Post-merger Financing
“Preliminary data will be reported in 2022.”
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Preliminary data for HIV studies
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ImmunityBio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IBRX-002816 · Corrections policy